Vir Biotechnology Stock Performance
| VIR Stock | USD 7.47 0.24 3.11% |
On a scale of 0 to 100, Vir Biotechnology holds a performance score of 11. The entity has a beta of 1.37, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vir Biotechnology will likely underperform. Please check Vir Biotechnology's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Vir Biotechnology's existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vir Biotechnology are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent forward indicators, Vir Biotechnology reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.11) | Five Day Return (0.27) | Year To Date Return 25.76 | Ten Year Return (46.72) | All Time Return (46.72) |
1 | Disposition of 227803 shares by Svf Endurance Ltd of Vir Biotechnology at 6.1491 subject to Rule 16b-3 | 11/24/2025 |
2 | Disposition of 235971 shares by Svf Endurance Ltd of Vir Biotechnology at 6.38 subject to Rule 16b-3 | 11/25/2025 |
3 | Disposition of 127938 shares by Svf Endurance Ltd of Vir Biotechnology at 6.391 subject to Rule 16b-3 | 11/26/2025 |
4 | VIR HC Wainwright Co. Reiterates Buy Rating with 15 Price Target VIR Stock News - GuruFocus | 12/30/2025 |
5 | Disposition of 22000 shares by Sato Vicki L of Vir Biotechnology at 5.9265 subject to Rule 16b-3 | 01/02/2026 |
6 | Insider Sell Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc - GuruFocus | 01/05/2026 |
7 | BofA Securities Maintains Vir Biotechnology With Buy Rating, Maintains Target Price 13 - | 01/13/2026 |
8 | Acquisition by George Scangos of 598270 shares of Vir Biotechnology subject to Rule 16b-3 | 01/16/2026 |
9 | Disposition of 14168 shares by Ann Hanly of Vir Biotechnology at 9.4534 subject to Rule 16b-3 | 01/28/2026 |
10 | Vir Biotechnology, Inc. Given Consensus Rating of Moderate Buy by Analysts | 01/30/2026 |
11 | Did Virs Advancing Hepatitis D Combo Program Just Shift Vir Biotechnologys Investment Narrative | 02/02/2026 |
12 | Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results | 02/09/2026 |
| Begin Period Cash Flow | 261.3 M | |
| Total Cashflows From Investing Activities | 499.4 M |
Vir Biotechnology Relative Risk vs. Return Landscape
If you would invest 544.00 in Vir Biotechnology on November 19, 2025 and sell it today you would earn a total of 203.00 from holding Vir Biotechnology or generate 37.32% return on investment over 90 days. Vir Biotechnology is generating 0.6268% of daily returns assuming volatility of 4.4892% on return distribution over 90 days investment horizon. In other words, 40% of stocks are less volatile than Vir, and above 88% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vir Biotechnology Target Price Odds to finish over Current Price
The tendency of Vir Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.47 | 90 days | 7.47 | about 7.83 |
Based on a normal probability distribution, the odds of Vir Biotechnology to move above the current price in 90 days from now is about 7.83 (This Vir Biotechnology probability density function shows the probability of Vir Stock to fall within a particular range of prices over 90 days) .
Vir Biotechnology Price Density |
| Price |
Predictive Modules for Vir Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vir Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vir Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vir Biotechnology is not an exception. The market had few large corrections towards the Vir Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vir Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vir Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.50 | |
β | Beta against Dow Jones | 1.37 | |
σ | Overall volatility | 0.72 | |
Ir | Information ratio | 0.12 |
Vir Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vir Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vir Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vir Biotechnology appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 74.2 M. Reported Net Loss for the year was (521.96 M) with loss before taxes, overhead, and interest of (427.98 M). | |
| Vir Biotechnology has about 2.2 B in cash with (446.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results |
Vir Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vir Stock often depends not only on the future outlook of the current and potential Vir Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vir Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 136.2 M | |
| Cash And Short Term Investments | 905.3 M |
Vir Biotechnology Fundamentals Growth
Vir Stock prices reflect investors' perceptions of the future prospects and financial health of Vir Biotechnology, and Vir Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vir Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (722.68) % | ||||
| Current Valuation | 632.23 M | ||||
| Shares Outstanding | 139.13 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 61.64 X | ||||
| Revenue | 74.2 M | ||||
| Gross Profit | (427.98 M) | ||||
| EBITDA | (508.91 M) | ||||
| Net Income | (521.96 M) | ||||
| Cash And Equivalents | 2.2 B | ||||
| Cash Per Share | 16.55 X | ||||
| Total Debt | 97.89 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.79 X | ||||
| Book Value Per Share | 5.73 X | ||||
| Cash Flow From Operations | (446.35 M) | ||||
| Earnings Per Share | (3.62) X | ||||
| Market Capitalization | 1.04 B | ||||
| Total Asset | 1.4 B | ||||
| Retained Earnings | (759.78 M) | ||||
| Working Capital | 922.8 M | ||||
About Vir Biotechnology Performance
Assessing Vir Biotechnology's fundamental ratios provides investors with valuable insights into Vir Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vir Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.34) | (0.35) | |
| Return On Equity | (0.52) | (0.50) |
Things to note about Vir Biotechnology performance evaluation
Checking the ongoing alerts about Vir Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vir Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vir Biotechnology appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 74.2 M. Reported Net Loss for the year was (521.96 M) with loss before taxes, overhead, and interest of (427.98 M). | |
| Vir Biotechnology has about 2.2 B in cash with (446.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results |
- Analyzing Vir Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vir Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Vir Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vir Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vir Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vir Biotechnology's stock. These opinions can provide insight into Vir Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.